论文部分内容阅读
目的:探讨血清半胱氨酸蛋白酶抑制剂C(CysC)水平检测对糖尿病早期肾功能损害的诊断意义。方法:将80例1型或2型糖尿病患者按尿白蛋白排泄率(UAER)分为3组,无糖尿病的正常人为1组。A组为20例无糖尿病的正常人。B组为正常蛋白尿患者32例(UAER<20μg/min);C组为微量蛋白尿患者29例(UAER20~200μg/min);D组为大量蛋白尿患者19例(UAER>200g/min);同时测定各组血肌酐及CystatinC,并计算肌酐清除率。结果:血清CystatinC和CCr在B、C、D三组间的差异有显著性(P<0.05),而Scr在B组和C组间的差异无显著(P>0.05),而C组的Scr高于A、B、D组,差异有显著性(P<0.05)。CystatinC在A组和B组间比较无显著性差异(P>0.05);C组、D组与A组、B组比较有显著性差异(P<0.001)。结论:CystatinC是临床上诊断早期糖尿病肾病的敏感指标之一。
Objective: To investigate the diagnostic value of serum cystatin C (CysC) level in the diagnosis of early diabetic renal damage. Methods: Eighty patients with type 1 or type 2 diabetes mellitus were divided into three groups according to urinary albumin excretion rate (UAER), and one group without diabetes. A group of 20 non-diabetic normal subjects. In group B, there were 32 cases with normal proteinuria (UAER <20μg / min), group C with microalbuminuria (UAER 20 ~ 200μg / min), group D with 19 cases with large proteinuria (UAER> 200μg / The serum creatinine and Cystatin C in each group were measured at the same time, and the creatinine clearance rate was calculated. Results: There were significant differences in serum Cystatin C and CCr between B, C and D groups (P <0.05), but there was no significant difference between Scr in group B and C (P> 0.05) Higher than A, B, D group, the difference was significant (P <0.05). Cystatin C had no significant difference between group A and group B (P> 0.05). There was significant difference between group C and group D and group A and group B (P <0.001). Conclusion: Cystatin C is one of the sensitive indicators in the diagnosis of early diabetic nephropathy.